![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Mehta Api Pvt. Ltd. Boisar In, based in India, is a pharmaceutical company that stands out with its certifications from EDQM and WHO-GMP.
They are recognized for Strategic partner for Innovator & Generic API companies for >50 years.
One of their significant offerings is Erythromycin, supported by a 'Withdrawn by EDQM Failure to CEP procedure' Certificate of Suitability (CEP) with the number R1-CEP 2009-267 - Rev 01
This Chemical Type CEP, issued on June 11, 2019, remains in force until November 14, 2019, ensuring its reliability within the pharmaceutical industry.
Substance Number 179 associated with this CEP further emphasizes